Dr Michael Streit | Sr Director Clinical Research Lead
Janssen

Dr Michael Streit, Sr Director Clinical Research Lead, Janssen

Michael Streit, MD serves as Senior Director and Clinical Research Leader in the Oncology Translational Medicine and Early Development Department at Janssen. He is responsible for the clinical development of a novel agonistic anti-CD40 antibody and involved in the management of an emerging portfolio of innovative immuno-therapeutic agents. Dr. Streit trained in Hematology and Medical Oncology at the Free University of Berlin (Germany) and spent 3 years as Research Instructor at the Massachusetts General Hospital (Harvard Medical School). Prior to joining Janssen, Dr. Streit held positions of increasing responsibility in discovery research at Berlex Biosciences and clinical development at Boehringer-Ingelheim, Bristol-Myers-Squibb, and Glaxo-Smith-Kline.

Appearances:



EAC 2017 Day 1, Tuesday 31st October 2017 @ 14:50

Collaborations between big pharma and biotechs – running a format through phase III and commercialisation

  • Innovative clinical development planning and implementation
  • Regulatory strategies for first-in-class compounds
  • Rationale combination strategies to expand and defend the approved asset
 

back to speakers